REMASTer: REcurrent Brain Metastases After SRS Trial

Randomized, post-market multi-center study investigating the efficacy of two sets of treatment algorithms in brain metastases (BM) patients at the time of first intervention for radiographic progression after stereotactic radiosurgery (SRS), with or without surgery.

Trial Details

NCT ID
NCT05124912
Phase
NA
Sponsor
Monteris Medical
Status
RECRUITING
Cancer Type
Brain Cancer
Interventions
  • Radiation Therapy
  • Steroid Therapy
  • Laser Interstitial Thermal Therapy
Locations (sample)
  • Los Angeles, California, United States|34.05223,-118.24368
  • Chicago, Illinois, United States|41.85003,-87.65005
  • Baltimore, Maryland, United States|39.29038,-76.61219
  • St Louis, Missouri, United States|38.62727,-90.19789
  • Durham, North Carolina, United States|35.99403,-78.89862

Key Eligibility Criteria

  • In order to be eligible to participate in this study, an individual must meet all of the following criteria:
  • Patients with radiographically proven (by gadolinium-enhanced \[Gd-\] MRI) parenchymal brain metastases from histologically confirmed non-central n…
  • Patients with a "targetable", bidimensionally-measurable, intracranial lesion that is radiographically recurrent after previous treatment with SRS …
  • Patient must be at least 3 months post initial SRS treatment of the target lesion

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Brain Cancer Trials on Trialify →